Meeting
2013 ASCO Annual Meeting
BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+ HER2- metastatic breast cancer.
Authors
William John Gradishar
Northwestern University, Chicago, IL
William John Gradishar , Thomas Denis Bachelot , Stephen Saletan , Anne Marie Graham , Pedro Emanuel Rubini Liedke , Sergio Jobim Azevedo , Virote Sriuranpong , Fatima Cardoso
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT01698918
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS661)
DOI
10.1200/jco.2013.31.15_suppl.tps661
Abstract #
TPS661
Poster Bd #
16D
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).
First Author: Erica L. Mayer
Poster
2017 ASCO Annual Meeting
Assessment of ESR1 and ERBB2 mutations in estrogen receptor positive (ER+) metastatic breast cancers (MBC).
First Author: Gargi D. Basu
Poster
2017 ASCO Annual Meeting
Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study.
First Author: Fatima Cardoso
Poster
2016 ASCO Annual Meeting
Phase II trial of CC-486, a DNA methyltransferase inhibitor, in combination with fulvestrant in postmenopausal women with ER+, HER2- metastatic breast cancer who have progressed on an aromatase inhibitor (AI).
First Author: Mario Campone